Research 1 800 flowers-com flws every problem is a gift

Friday, March 20, 2020

1-800-Flowers.com (FLWS)

Every Problem Is A Gift

1-800-FLOWERS.COM, Inc. is the leading provider of gourmet and floral gifts for all occasions. For nearly 40 years, 1-800-FLOWERS® has been helping deliver smiles for customers with gifts for every occasion, including fresh flowers, premium, gift-quality fruits, and other gourmet items from Harry & David®, popcorn and specialty treats from The Popcorn Factory®; cookies and baked gifts from Cheryl’s®; premium chocolates and confections from Fannie May®; gift baskets and towers from 1-800-Baskets.com®; premium English muffins and other breakfast treats from Wolferman’s; carved fresh fruit arrangements from FruitBouquets.com; and top quality steaks and chops from Stock Yards®. The Company’s BloomNet® international floral wire service provides a broad range of quality products and value-added services designed to help professional florists grow their businesses profitably.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Marketing highlights. This report highlights a recent market trip to Chicago two weeks ago with William Shea, CFO, and Joe Pittito, IR. We believe that the message to investors is that the company is geared up for its recent acquisition and capable of weathering the current economic uncertainty.

    Adds A Personal Touch. The company is nearing the closing (early April) of PersonalizationMall.com for $252 million. We view the acquisition favorably as it expands its everyday gifting platform, further distances itself from its peers that have a…



    Click here to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Capitalism Versus Coronavirus

Current Efforts to Combat Coronavirus Pandemic

(Note: companies that
could be impacted by the content of this article are listed at the base of the
story [desktop version]. This article uses third-party references to provide a
bullish, bearish, and balanced point of view; sources are listed after the
Balanced section.)

Current Efforts to Combat Coronavirus Pandemic

As the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, rapidly spreads around the globe, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines.

Exhibit 7. Selected Companies Combatting Coronavirus

Unsupported image type.

Source: Noble Capital

The outbreak gave rise to an active business development environment for deal-making to create join ventures and collaborations focused on the development of an effective therapy. In addition to multiple academic collaborations, recent industry deals include:

  • Abcellera with Eli Lilly
  • BioNtech with Pfizer
  • Generex with Epivax
  • Vaxart with Emergent BioSolutions
  • Vir collaborating with Biogen and Alynam

On the therapeutic side, Gilead’s remdesivir was the first drug to enter the clinic against coronavirus. Remdesivir was initially tested in humans with Ebola virus disease and has shown promise in animal models for MERS and SARS. Two ongoing Phase 3 studies are assessing Remdesivir (that blocks RNA polymerase) for the treatment of COVID-19 in the United States and China.  These randomized, open-label, multicenter studies will have readouts anticipated in April 2020.

Sanofi and Regeneron Pharmaceuticals have started a clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19. Kevzara is an interleukin-6 (IL-6) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in 2017 to treat adults with moderately to severely active rheumatoid arthritis. The U.S.-based trial is expected to begin in New York, to assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo. The multi-center, double-blind, Phase 2/3 trial has an adaptive design. The data is anticipated to readout in April 2020.

Roche and Genentech also initiated a Phase 3 trial of Actemra in hospitalized patients with severe COVID-19 pneumonia in China and Italy. The primary and secondary endpoints of the trial include clinical status, mortality, mechanical ventilation, and ICU variables. Actemra, an interleukin-6 (IL-6) receptor antagonist, was approved by the FDA in 2010 for the treatment of moderately to severely active rheumatoid arthritis (RA) patients.

Can-Fite BioPharma (CANF) is also exploring piclidenoson (A3 adenosine receptor agonist (A3AR) small molecule) on Coronaviruses viral load in a mammalian cell model system in collaboration with the Lewis Katz School of Medicine at Temple University, Philadelphia. Piclidenoson is currently in Phase 3 clinical stage for the treatment of patients with rheumatoid arthritis and it has anti-viral effects against single stranded RNA viruses.

Cocrystal is collaborating with Kansas State University Research Foundation (KSURF) to further develop proprietary broad-spectrum antiviral compounds for the treatment of Norovirus and Coronavirus infections. Cocrystal uses structure-based technologies to identify antiviral drugs. 

CytoDyn (CYDY) is developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications. The company submitted an investigational new drug (IND) application to the FDA to conduct a Phase 2 clinical trial with leronlimab (PRO 140) as a therapy for patients who experience respiratory complications as a result of contracting COVID-19.

On the vaccine front, among over 40 vaccines are in development, Moderna’s mRNA-1273 is the only one currently in the clinic. Moderna generates vaccines that contain nucleic acids with genetic codes (mRNA sequence). These codes instruct the body’s cells to synthesize certain proteins from the virus that don’t infect a person but activate an immune response. On March 16, the first patient was dosed with mRNA-1273 and Moderna became the second company to enter the clinic to combat coronavirus following Gilead. The open-label trial will be tested on 45 healthy volunteers between the ages of 18 and 55, according to ClinicalTrials.gov over approximately six weeks. The volunteers will be divided into three groups, each of which will receive a different dosage. Results from the Phase 1 trial are expected in June.

Dyadic is collaborating with The Israel Institute for Biological Research (IIBR) to develop therapeutics against Covid-19. As per the collaboration, IIBR will develop potential candidates and Dyadic will use their C1 technology to manufacture vaccines and monoclonal antibodies. C1 expression system is at the discovery stage to manufacture large volumes of low-cost biologic products such as enzymes and proteins.

Generex Biotechnology (GNBT) has signed a contract with EpiVax to use their computational tools to predict epitopes that can be used to generate peptide vaccines against the Covid-19 using the patented NuGenerex Immuno-Oncology (NGIO – Formerly Antigen Express) Ii-Key technology. EpiVax has identified a number of “hotspots” in the amino acid sequences of the nCOV-2019 coronavirus proteins. Using the epitopes predicted by EpiVax, Generex will manufacture a series of synthetic amino acid peptides that mimic the epitopes of the virus and send them to China for testing. EpiVax is collaborating with University of Georgia to develop a novel coronavirus SARS-CoV -2 (COVID-19) vaccine.

Heat Biologics (HTBX) is developing therapeutic vaccines in collaboration with the University of Miami to support the development of a vaccine leveraging Heat’s proprietary gp96 platform designed to target the SARS-CoV-2 coronavirus that causes COVID-19.

Tonix Pharmaceuticals announced a collaboration with Southern Research to develop a vaccine TNX-1800 against Covid-19. The company is using its proprietary horsepox virus vector platform for the development of TNX-1800. Tonix has previously reported that horsepox has efficacy as a vaccine and good tolerability in mice and cynomolgus macaques. 

Vaxart uses a specific virus called adenovirus type 5 (Ad5) as part of its novel technology platform to help train the immune system to recognize and defeat dangerous invading pathogens. The Ad5 virus serves as a vector to deliver the antigen and booster molecules to stimulate immune responses. The antigen is the pathogen protein designed to trigger the targeted immune response and the booster molecule is an adjuvant that stimulates and adds to the immune response. Vaxart can use the same vector with different antigens to provide an effective standardized and scalable approach for vaccine development. Vaxart’s approach to develop a vaccine for Covid-19 involves generating potential vaccine candidates based on the published genome of the 2019 Novel Coronavirus (2019-nCoV).

Suggested Reading:

Everything You Always Wanted to Know About Coronavirus

Research – InPlay Oil (IPOOF) – Results in line but dark clouds growing

Thursday, March 19, 2020

InPlay Oil (IPOOF)

Results in line but dark clouds growing

InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQZ Exchange under the symbol IPOOF.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Operational results strong. The company met production guidance with 7% year over year growth. Operating costs continue to decline (2019 LOE of $14.36/BBL vs $16.02). Reserves are being replaced (120% reserve replacement) even as the company limits cap exp to a level below operating cash flow. All in all, this was a good year for the company on an operational side as positive trends that have developed in recent years continued.

    Financial results slightly below expectations. Realized oil and gas prices were near expectations (oil slightly below and gas above) leading to revenues being near expectations. Operating netbacks (sales less royalties, transportation and operating costs) were generally in line for the quarter and year. The same can be said for adjusted fund flow for the quarter and year which came in at $7.9 and $32.5 million versus our $8.2 and $34.2 million estimates. EPS of $(0.28) and $(0.39) were well below our $(0.01) and $(0.12) estimates. We speculate that interest expense and income taxes were greater than expected. Indeed, net debt levels…


    Click here to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Gevo, Inc. (GEVO) – Supply Agreements Bolster Financing Discussions.

Thursday, March 19, 2020

Gevo, Inc. (GEVO)

Supply Agreements Bolster Financing Discussions.

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment and the Gevo Development/Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Gevo Development/Agri-Energy is the key revenue generating segment which involves the operation of the Luverne Facility and production of ethanol, isobutanol and related products.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Narrower 4Q2019 loss in line with expectations. No change in 2020 estimates. Adjusted EBITDA of $(4.0) million was down from $(4.9) million in 4Q2018 as higher hydrocarbon more than offset lower ethanol production.

    Solid progress on Phase 1 goal to lower carbon intensity. The startup of wind energy and the upcoming move to renewable natural gas (RNG) use are signs of progress on Phase 1. Contracts with three dairies support RNG buildout to lower carbon intensity. Added hydrocarbon production is…

    >


    Click here to Get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research inplay oil ipoof results in line but dark clouds growing

Thursday, March 19, 2020

InPlay Oil (IPOOF)

Results in line but dark clouds growing

InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQZ Exchange under the symbol IPOOF.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Operational results strong. The company met production guidance with 7% year over year growth. Operating costs continue to decline (2019 LOE of $14.36/BBL vs $16.02). Reserves are being replaced (120% reserve replacement) even as the company limits cap exp to a level below operating cash flow. All in all, this was a good year for the company on an operational side as positive trends that have developed in recent years continued.

    Financial results slightly below expectations. Realized oil and gas prices were near expectations (oil slightly below and gas above) leading to revenues being near expectations. Operating netbacks (sales less royalties, transportation and operating costs) were generally in line for the quarter and year. The same can be said for adjusted fund flow for the quarter and year which came in at $7.9 and $32.5 million versus our $8.2 and $34.2 million estimates. EPS of $(0.28) and $(0.39) were well below our $(0.01) and $(0.12) estimates. We speculate that interest expense and income taxes were greater than expected. Indeed, net debt levels…


    Click here to get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research gevo inc- gevo supply agreements bolster financing discussions

Thursday, March 19, 2020

Gevo, Inc. (GEVO)

Supply Agreements Bolster Financing Discussions.

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment and the Gevo Development/Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Gevo Development/Agri-Energy is the key revenue generating segment which involves the operation of the Luverne Facility and production of ethanol, isobutanol and related products.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Narrower 4Q2019 loss in line with expectations. No change in 2020 estimates. Adjusted EBITDA of $(4.0) million was down from $(4.9) million in 4Q2018 as higher hydrocarbon more than offset lower ethanol production.

    Solid progress on Phase 1 goal to lower carbon intensity. The startup of wind energy and the upcoming move to renewable natural gas (RNG) use are signs of progress on Phase 1. Contracts with three dairies support RNG buildout to lower carbon intensity. Added hydrocarbon production is…

    >


    Click here to Get the full report.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research energy fuels inc- uuuu full year loss greater than expected due to inventory impairment

Wednesday, March 18, 2020

Energy Fuels Inc. (UUUU)

Full Year Loss Greater than Expected Due to Inventory Impairment

Energy Fuels Inc together with its subsidiary is engaged in the extraction and recovery of uranium properties in the United States. The company operates in two segments, ISR Uranium and Conventional Uranium. It conducts its ISR activities through its Nichols Ranch Project, located in northeast Wyoming. It conducts its conventional uranium extraction and recovery activities through its White Mesa Mill. In addition, the group also owns uranium and uranium, vanadium properties and projects in various stages of exploration, permitting, and evaluation. Energy Fuels derives most of the income through the sale of Uranium.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Full year 2019 results. Energy Fuels reported fourth quarter and full year 2019 losses per share of ($0.10) and ($0.40), respectively. We had predicted fourth quarter and full year losses of ($0.06) and ($0.36) per share. The variance to our estimate was due, in part, to an inventory impairment charge that was partially offset by higher revenues and lower expense.

    Government purchase program.  President Trump’s 2021 budget proposal includes $150 million to fund a strategic uranium reserve to provide assurance of uranium supplies and to support U.S. nuclear fuel cycle capabilities through the domestic production and conversion of uranium. Assuming no changes by the time an appropriations bill is signed into law by September 30, purchases could begin in fiscal year 2021 which begins October 1. Industry participants are awaiting more details on the program and…



    Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research orion group holdings orn new marine awards support current outlook

Wednesday, March 18, 2020

Orion Group Holdings (ORN)

New Marine Awards Support Current Outlook.

Orion Group Holdings, based in Houston, Texas, is a specialty construction company within the Marine and Industrial Construction sectors, with operations focused in the continental United States and Caribbean. Revenue is split roughly 50/50 between a Marine Construction segment that provides marine facility, pipeline and structural construction services and a Commercial Concrete segment that provides turnkey concrete services in the light commercial and structural construction markets.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Two Marine jobs awarded for total of $24 million. Energy infrastructure related work along the Gulf Coast begins shortly and should finish by year-end 2020. Positive sign given the sharp drop in crude oil prices.

    New work moves total announced YTD 2020 awards to $111 million. Marine awards total $71 million and Concrete awards total $40 million. Additional awards seem likely since other low bids pending awards from…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Here’s Your Stimulus Check, Now What?

The ”Coronavirus Economy,” will Washington “Go Big?”

The health of the U.S. economy depends on in-person interactions among its citizens. Additionally, as a major global trading partner, it also relies on overseas economies with which to transact. At an increasing pace, over the last month, our trading partners have brought the pace of commerce down significantly. Both internally and externally, all “non-essential” transactions are at a crawl. In just the past two weeks, the subject of the coronavirus has gone from the punchline of jokes at the office watercooler to the reason people no longer use the office water cooler.  There is now a semi-mandatory freeze on interacting with our co-workers, friends, neighbors, and service industry workers. We have brought the U.S. economy from its “90 mph pace” in February to a mid-March standstill. Unlike other slowdowns, we’re not out of gas. So, what can be done?

Sedate or
Stimulate?

The lack of transactions (economic activity) has been orchestrated and to one degree or another required. We are now in the midst of economic malaise. In the past, the tools for fighting economic malaise was lead by a targeted approach to cause banks to lend more, companies to hire more, or people to spend more. In the current situation it would seem that stimulus while forcing people and businesses to be less than simulative, is a lost cause.

The two opposing forces could turn out to be more costly than effective. The Federal Reserve Bank has slashed overnight bank lending rates to near zero over just a few weeks. Lower rates is their tool used to accelerate lending and the accompanying economic activity as it promotes increased spending and investment. It also helps, at least initially, banks who improve their profitability because they now have access to a cheaper cost of money against higher interest rate loans. The likelihood that slashing Fed funds to near zero will have the same impact as in the past seems very low. We are being incentivized to spend while urged to hunker down.

At the same time that the Fed announced its second rate cut of the year (only nine days after a very strong employment report), they also announced additional actions, which included buying $500 billion or more of U.S. Treasuries. Along with the Treasuries, they said they would purchase Federal agency mortgaged back securities totaling over $200 billion or more. The positive effect of the Fed buying securities in the open market on a wholesale level is twofold. First, it adds cash, in this case, over $700 billion, into the economy. Putting cash into the market in this way is the simulative practice dubbed quantitative easing during the 2008 financial crisis. Secondly, it lowers interest rates even further in that it dramatically increases demand on longer-term securities. The lower rates are intended to reduce the cost of money, allowing individuals and companies to borrow (and therefore spend) at a lower rate. Not unlike cutting Fed Funds, it is to promote activity — Activity that we are restricted or discouraged from taking part in. At the same time, it creates another problem, senior citizens, the age group expected to be most at risk to the coronavirus, depend on income generated from CDs and fixed income securities. The impact of the health crisis, especially to older people, and the reaction, has created another cause for problems to older people, income.

Old
Habits

Reason suggests that trying to sedate activity while at the same time stimulating it is like washing melatonin down with Red Bull to get a good night of rest. Both seem to work against each other. The government reaction to economic headwinds has always been to stimulate using the methods described above. This new problem has a completely different set of circumstances. The economy was breaking records in many categories just weeks ago. Yet now, the likelihood of a recession (two or more consecutive quarters of negative GDP) seems unavoidable. Under most predictions related to the guidance to minimize interacting with others, we will be crawling into mid-Summer.

The latest plans being discussed in Washington are also being called stimulus plans. Using “stimulus” to describe them may be out of habit, or to try to get them passed, but they are not intended to fire up the economy. Instead, the intention is to help bridge the needs of households until we can all get back to work. If government help is needed, bridging the gap and tending to the health issue until people can begin consuming again is a useful response.

Going Big
on a Bridge Plan

 President Trump is determined to lead the country out of the health crisis while minimizing damage to citizens and the businesses that employ them. He had been discussing the idea of a payroll tax cut with his advisors. The payroll tax cut would help small businesses and individuals as long as the businesses remained open. This doesn’t help businesses that are not open. The people and businesses that will be most hurt by the dramatic downshift of the economy will be those without pay or payroll because they’re idle. Even companies that are open, with reduced business and workers with reduced wages, would have a long wait for the benefit of any payroll tax cut.

It was just announced that taxpayers have been given the flexibility of delaying 90 days to pay their taxes to the IRS. The White House has also asked for legislation to include support for small businesses and aid to the airline industry, and other measures for industries hurt by the slowdown. As it relates directly to households, U.S. Treasury Secretary Steven Mnuchin said they plan to put money in people’s hands now. His exact words are: “And when I say now, I mean in the next two weeks, not six to eight months under tax relief.”

The most recent plan being discussed in the Senate and the Administration is a package from $1 trillion to $1.2 trillion which would include cash payments, loan guarantees, and a host of “kitchen sink” items designed to bridge business and their workers to the other side of this crisis. One of the most talked-about items on that list is a one-time payment of $1,000 to workers directly from the U.S. Treasury.

While we
Wait

Anyone in Washington delaying a plan that will help relieve people who are rightfully concerned for their financial security risks losing the next election. This is a time of national crisis, and there seems to be more of an air of unity, with only mild positioning.  With this, we should begin to see “bridging” actions put into play.

For those stuck at home, finding your own way to bridge the gap before returning to your normal work environment, being as productive as possible will help. Strengthening your own infrastructure, whether that means Spring cleaning, or setting up an efficient home office will help your productivity now, and on the other side of the crisis.

If you own or are with a company that is still open but not at capacity, this may be the time to build on your own infrastructure. Look at the improvements that you can make to slingshot back up to speed when we are passed this. Depending on your business, a marketing plan may be in order to stay in front of customers and investors throughout. Your competition may be distracted by news events; this could be the best time to move forward and come out ahead

Suggested
Reading:

Bear Market Cycles, is it Different
this Time?

ZIRP and QE5

 

Sources: https://www.washingtonpost.com/us-policy/2020/03/17/trump-coronavirus-stimulus-package/

https://www.bloomberg.com/news/articles/2020-03-17/mnuchin-says-trump-wants-money-sent-to-americans-in-two-weeks

Research helix biopharma hbpcf improved cash position bodes well for future prospects

Wednesday, March 18, 2020

Helix Biopharma (HBPCF)

Improved Cash Position Bodes Well for Future Prospects

Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Unique Technology Targeting Tumor Microenvironment (TME). We view Helix Biopharma as a pioneer in the cancer area as the company is developing a platform technology targeting the tumor microenvironment. Helix’s technology is designed to reduce tumor acidity, an escape mechanism which cancer cells utilize to evade the anti-tumor immune response. Tumor acidity has been shown to correlate with resistance to anti-cancer treatment and poor prognosis for cancer patients.

    Lead drug L-DOS47 for the Treatment of Cancer. Helix Biopharma’s lead drug, L-DOS47, is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. In a clinical trial using L-DOS47 as a mono-therapy for the treatment of NSCLC, treated patients showed reductions in tumor size and…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Energy Fuels Inc. (UUUU) – Full Year Loss Greater than Expected Due to Inventory Impairment

Wednesday, March 18, 2020

Energy Fuels Inc. (UUUU)

Full Year Loss Greater than Expected Due to Inventory Impairment

Energy Fuels Inc together with its subsidiary is engaged in the extraction and recovery of uranium properties in the United States. The company operates in two segments, ISR Uranium and Conventional Uranium. It conducts its ISR activities through its Nichols Ranch Project, located in northeast Wyoming. It conducts its conventional uranium extraction and recovery activities through its White Mesa Mill. In addition, the group also owns uranium and uranium, vanadium properties and projects in various stages of exploration, permitting, and evaluation. Energy Fuels derives most of the income through the sale of Uranium.

Mark Reichman, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Full year 2019 results. Energy Fuels reported fourth quarter and full year 2019 losses per share of ($0.10) and ($0.40), respectively. We had predicted fourth quarter and full year losses of ($0.06) and ($0.36) per share. The variance to our estimate was due, in part, to an inventory impairment charge that was partially offset by higher revenues and lower expense.

    Government purchase program.  President Trump’s 2021 budget proposal includes $150 million to fund a strategic uranium reserve to provide assurance of uranium supplies and to support U.S. nuclear fuel cycle capabilities through the domestic production and conversion of uranium. Assuming no changes by the time an appropriations bill is signed into law by September 30, purchases could begin in fiscal year 2021 which begins October 1. Industry participants are awaiting more details on the program and…



    Get the full report on Channelchek desktop.

This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Helix Biopharma (HBPCF) – Improved Cash Position Bodes Well for Future Prospects

Wednesday, March 18, 2020

Helix Biopharma (HBPCF)

Improved Cash Position Bodes Well for Future Prospects

Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Unique Technology Targeting Tumor Microenvironment (TME). We view Helix Biopharma as a pioneer in the cancer area as the company is developing a platform technology targeting the tumor microenvironment. Helix’s technology is designed to reduce tumor acidity, an escape mechanism which cancer cells utilize to evade the anti-tumor immune response. Tumor acidity has been shown to correlate with resistance to anti-cancer treatment and poor prognosis for cancer patients.

    Lead drug L-DOS47 for the Treatment of Cancer. Helix Biopharma’s lead drug, L-DOS47, is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. In a clinical trial using L-DOS47 as a mono-therapy for the treatment of NSCLC, treated patients showed reductions in tumor size and…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Research – Orion Group Holdings (ORN) – New Marine Awards Support Current Outlook.

Wednesday, March 18, 2020

Orion Group Holdings (ORN)

New Marine Awards Support Current Outlook.

Orion Group Holdings, based in Houston, Texas, is a specialty construction company within the Marine and Industrial Construction sectors, with operations focused in the continental United States and Caribbean. Revenue is split roughly 50/50 between a Marine Construction segment that provides marine facility, pipeline and structural construction services and a Commercial Concrete segment that provides turnkey concrete services in the light commercial and structural construction markets.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Two Marine jobs awarded for total of $24 million. Energy infrastructure related work along the Gulf Coast begins shortly and should finish by year-end 2020. Positive sign given the sharp drop in crude oil prices.

    New work moves total announced YTD 2020 awards to $111 million. Marine awards total $71 million and Concrete awards total $40 million. Additional awards seem likely since other low bids pending awards from…



    Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.